Abstract Cefiderocol, formerly S-649266, is a first in its class, an injectable siderophore
cephalosporin that combines a catechol-type siderophore and cephalosporin core with side …

Cefiderocol (CFDC),(formerly S‐649266), is a novel injectable siderophore cephalosporin
developed by Shionogi & Co., Ltd., with potent in vitro activity against Gram‐negative …

Cefiderocol is an injectable siderophore cephalosporin discovered and being developed by
Shionogi & Co., Ltd., Japan. As with other β-lactam antibiotics, the principal antibacterial …

Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a
“Trojan horse” active transport mechanism to enter bacteria and has proven in vitro activity …

Bacterial resistance to carbapenem agents has reached alarming levels. Accordingly,
collaborative efforts between national and international organizations and the …

The emergence of antimicrobial resistance is a significant public health issue worldwide,
particularly for healthcare-associated infections caused by carbapenem-resistant gram …

Cefiderocol is a parenteral siderophore cephalosporin with a catechol-containing 3′
substituent. We evaluated its MICs against Gram-negative bacteria, using iron-depleted …

Abstract Intravenous cefiderocol (Fetroja®; Fetcroja®) is the first siderophore cephalosporin
approved for the treatment of adults with serious Gram-negative bacterial infections …

Objective: This article reviews the available data on the chemistry, spectrum of activity,
pharmacokinetic and pharmacodynamic properties, clinical efficacy, and potential place in …

ABSTRACT Cefiderocol (formerly S-649266) is a novel siderophore-conjugated
cephalosporin with activity against a broad array of multidrug-resistant (MDR), aerobic Gram …